Scarica l'app Stockscreener
2.91
6.13%
-0.19
Dopo l'orario di chiusura:
2.81
-0.10
-3.44%
Vyome Holdings Inc Borsa (HIND) Ultime notizie
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
HIND Should I Buy - Intellectia AI
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Reviewing Vyome (HIND) and The Competition - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment By Investing.com - Investing.com South Africa
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results - BioSpace
Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Penny Stocks To Follow Now – January 27th - Defense World
Recommendations-Union Budget FY27, Vyome Holdings, Inc. - Medical Buyer
Vyome Holdings Highlights VT-1953 Market Potential Analysis - TipRanks
Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView
Vyome Holdings Stock Tumults After Strategic Moves in Europe - timothysykes.com
Hindustan Diverges: Financial Snapshot Paints Varied Picture - StocksToTrade
Vyome Holdings Eyes Growth Amid Market Turbulence - timothysykes.com
Vyome stock soars after analyst values lead drug candidate at $1 billion - Investing.com Canada
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire
Vyome (NASDAQ:HIND) and Medline (NASDAQ:MDLN) Critical Survey - Defense World
“Malignant fungating wounds remain significantly under-recognised and under-treated in India” - BioSpectrum India
HIND Forecast — Price Prediction for 2026. Should I Buy HIND? - Intellectia AI
MarketsMedicine Hat NewsMedicine Hat NewsVyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - FinancialContent
Vyome’s LiveChain signs LOI for Humanyze note acquisition - MSN
Vyome Therapeutics2026 Latest Shareholding - Tracxn
Vyome Holdings, Inc. (HIND) Competitors - Meyka
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate - Yahoo Finance
What is the current Price Target and Forecast for Vyome Holdings, Inc. (HIND) - Zacks Investment Research
Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition - TipRanks
Vyome Holdings Signs Letter of Intent With Remus Capital Series B II - TradingView — Track All Markets
Vyome Holdingson Dec 17, Entered Binding L - 富途牛牛
Vyome Subsidiary LiveChain Signs LOI to Take Control of Humanyze Assets - citybiz
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company - Yahoo Finance
Pomichter Stanley D Iii Net Worth (2026) - GuruFocus
Mohanjit Jolly Net Worth (2025) - GuruFocus
Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market - BioSpectrum India
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN
Check Out Vyome Holdings Inc (HIND)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval - BioSpace
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):